2-phenyl-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one | 1190305-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
• 英文别名: 2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one；2-phenyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
• CAS: 1190305-61-3
• 化学式: C₁₁H₈N₄O
• 分子量: 212.211
• InChiKey: OQHWVAQCLKFQMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  原甲酸三乙酯 、 4-氨基-1-苯基-1H-吡唑-3-甲酸 在 ammonium acetate 作用下， 反应 0.25h， 以25%的产率得到2-phenyl-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
  参考文献：
  名称：

  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition

  摘要：

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.

  DOI：

  10.1021/jm900718w

文献信息

• [EN] SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS<br/>[FR] DERIVES DE TRIAZOLES SUBSTITUES EN TANT QU'ANTAGONISTES DE L'OXYTOCINE
  申请人：PFIZER LTD

  公开号：WO2005028452A1

  公开（公告）日：2005-03-31

  The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing, said, inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

  本发明涉及一类具有催产素拮抗活性的取代1,2,4-三唑化合物（I）的用途，其制备方法以及含有该类抑制剂的组合物。这些抑制剂在包括性功能障碍在内的多种治疗领域具有用途，特别是早泄（P.E.）。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：UNIV DEGLI STUDI DI SIENA

  公开号：WO2020245759A1

  公开（公告）日：2020-12-10

  The present invention relates to compounds of formula (I) their salts and derivatives. Further object of the present invention are compositions, which comprise at least one compound of formula (I) or its pharmaceutically acceptable salts and derivatives and excipients and, optionally, a further active compound. Further object of the present invention are compounds of formula (I) or compositions which comprise them for use as antibacterial agents.

  本发明涉及式（I）化合物及其盐和衍生物。本发明的另一个目标是包含至少一种式（I）化合物或其药学上可接受的盐和衍生物以及辅料，可选地，还包括另一种活性化合物的组合物。本发明的另一个目标是将式（I）化合物或包含它们的组合物用作抗菌剂。
• SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS
  申请人：Pfizer Limited

  公开号：EP1673355A1

  公开（公告）日：2006-06-28
• 2-Phenylpyrazolo[4,3-<i>d</i>]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition
  作者：Ombretta Lenzi、Vittoria Colotta、Daniela Catarzi、Flavia Varano、Daniela Poli、Guido Filacchioni、Katia Varani、Fabrizio Vincenzi、Pier Andrea Borea、Silvia Paoletta、Erika Morizzo、Stefano Moro

  DOI：10.1021/jm900718w

  日期：2009.12.10

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.